Literature DB >> 8435805

Mass screening for endometrial cancer directed in risk groups of patients with diabetes and patients with hypertension.

M Grönroos1, T A Salmi, M H Vuento, E A Jalava, J E Tyrkkö, J I Maatela, A R Aromaa, R Siegberg, E R Savolainen, T V Kauraniemi.   

Abstract

BACKGROUND: The interest in mass screening programs for the early detection of endometrial cancer (EC) has grown with the rising incidence of this disease. Preliminary programs directed at asymptomatic women with only one risk factor, i.e. age, have not been cost-effective.
METHODS: In the current study, 597 asymptomatic women from 45-69 years of age with diabetes and/or hypertension were screened by Vabra (Berkeley Medevices Inc., Berkeley, CA) aspiration.
RESULTS: Among the women with diabetes, 6.3% preinvasive lesions of the endometrium were found. This is significantly more than the rate among women with hypertension, which was 1.3% (P < 0.01).
CONCLUSIONS: Regular mass screening programs for the early detection of EC should be directed at asymptomatic diabetic women 45 years of age or older. This study does not indicate that similar screenings would be effective for women with hypertension.

Entities:  

Mesh:

Year:  1993        PMID: 8435805     DOI: 10.1002/1097-0142(19930215)71:4<1279::aid-cncr2820710418>3.0.co;2-4

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  3 in total

1.  Slit2 overexpression results in increased microvessel density and lesion size in mice with induced endometriosis.

Authors:  Sun-Wei Guo; Yu Zheng; Yuan Lu; Xishi Liu; Jian-Guo Geng
Journal:  Reprod Sci       Date:  2012-08-08       Impact factor: 3.060

2.  Screening for endometrial cancer.

Authors:  M L Hicks; G Parham; S A Jenkins
Journal:  J Natl Med Assoc       Date:  1994-08       Impact factor: 1.798

3.  Increased immunoreactivity to SLIT/ROBO1 in ovarian endometriomas: a likely constituent biomarker for recurrence.

Authors:  Fanghua Shen; Xishi Liu; Jian-Guo Geng; Sun-Wei Guo
Journal:  Am J Pathol       Date:  2009-07-16       Impact factor: 4.307

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.